Ligand Directed Functional Selectivity of G-Protein Coupled Receptor Signalling
G 蛋白偶联受体信号转导的配体定向功能选择性
基本信息
- 批准号:7901579
- 负责人:
- 金额:$ 31.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-01 至 2013-07-31
- 项目状态:已结题
- 来源:
- 关键词:Adenylate CyclaseAdverse effectsAffinityAgonistArrestinsAutoreceptorsBehaviorBindingBinding ProteinsBrainCell LineCellsComplementComplexCouplingDNA Sequence RearrangementDataDevelopmentDiseaseDissociationDopamine AgonistsDopamine D2 ReceptorDopamine ReceptorDrug Delivery SystemsElementsEndocrine System DiseasesEnzymesEventExposure toFamilyG Protein-Coupled Receptor SignalingG protein-coupled inwardly-rectifying potassium channelG-Protein-Coupled ReceptorsGTP-Binding ProteinsGenesGuanine NucleotidesHeterotrimeric GTP-Binding ProteinsHormonesHumanIntracellular MembranesIon ChannelLigandsLightMembrane ProteinsMental disordersMidbrain structureMitogen-Activated Protein KinasesModelingMolecularMolecular ConformationMusMutationNatureNeuronsNeurosecretory SystemsNeurotransmitter ReceptorNeurotransmittersNucleus AccumbensOutcomePathway interactionsPatternPeptide Signal SequencesPharmaceutical PreparationsPharmacologic SubstancePharmacologyPharmacotherapyPopulationPreparationProcessProtein IsoformsProtein SubunitsProteinsPublishingQuinpiroleRattusReceptor ActivationReceptor SignalingRelative (related person)ResearchResistanceRoleSchizophreniaSignal PathwaySignal TransductionSmall Interfering RNASpecific qualifier valueSpecificityStimulusSubstance abuse problemSynapsesSystemTechnologyTestingTheoretical StudiesTissuesTransmembrane Domainarrestin 2basedesensitizationdimerdopamine D3 receptordrug developmentfunctional outcomesintermolecular interactionmemberneuropsychiatrynovelprotein complexpublic health relevancereceptorreceptor couplingresearch studyresponsestoichiometrytheoriestherapy outcometrafficking
项目摘要
DESCRIPTION (provided by applicant): Transduction of many external stimuli (e.g. light, odorants, neurotransmitters, hormones) by cells in all tissues occurs through activation of members of a large gene superfamily called G-protein coupled receptors (GPCRs) that couple receptor activation to complex cascades of signaling events through a vast and expanding array of intracellular and membrane bound proteins. A common feature of the transduction process for GPCRs is the intermediation of heterotrimeric G-proteins. Upon agonist binding to GPCRs, dissociation or rearrangement of the cognate G1 and G23 subunits is thought to trigger stimulation or inhibition of various enzymes, ion channels, and other effector molecules. Classical receptor theory suggests that any agonist of a specific GPCR will induce the same conformational changes, and that differences in efficacy and potency among agonists reflect only the coupling efficiency (strength of signal) and relative binding affinity. Recent evidence for a number of GPCRs has alternatively suggested the existence of ligand-specific conformations that preferentially traffic receptor activation to select subsets of signaling pathways resulting in distinct signal cascades for different agonists through the same GPCR isoform. In the case of the human D2 dopamine receptor, we have discovered selective activation patterns (potency and intrinsic activity) for K and Ca channels, adenylyl cyclase, and MAP kinase upon exposure to the agonists quinpirole, DHX, and NPA. The underlying molecular mechanisms for this "functional selectivity" of agonist action are unknown. In the proposed research we will examine mechanisms underlying functional receptor-signal complexes in the neuroendocrine AtT20 cell line and primary rat neurons through four specific aims: (1) To define ligand- dependent selectivity of D2 and D3 dopamine receptors coupled to five effectors; adenylyl cyclase (AC), Kir3.0 channels, CaV2.0 channels, p42/44 MAP kinase (Erk1/2), and 2-arrestin translocation. (2) To assess the parameters of functional selectivity for native D2 receptor signaling in rat midbrain neurons. (3) To test the contribution of conserved residues in transmembrane domains (TM2, TM5, TM7) and intracellular loops previously shown to be signal switches in other GPCRs to functional selectivity of agonist signaling through D2 receptors. (4) To test the hypothesis that specific receptor/G1-protein complexes confer agonist-dependent functional selectivity. These experiments will increase understanding of the role of intermolecular interactions in specifying the potency and efficacy of dopaminergic ligands and, in turn, will have impact on the development of drugs targeted toward several neuropsychiatric and endocrine disorders.
PUBLIC HEALTH RELEVANCE: This research explores the molecular basis for a novel signaling phenomenon, termed "functional selectivity", by which different drugs and neurotransmitters can direct very different signaling outcomes through the same isoform of neurotransmitter receptor. We will focus on an important class of dopamine receptors widely implicated in substance abuse behaviors as well as several psychiatric disorders such as schizophrenia. As the receptors are important targets for pharmaco-therapies, the outcome of our research will guide the development of more refined and specific drugs for these disorders with fewer side effects.
描述(由申请人提供):所有组织中的细胞对许多外部刺激(例如光、气味、神经递质、激素)的转导是通过激活称为 G 蛋白偶联受体 (GPCR) 的大型基因超家族的成员来实现的,该基因超家族与受体激活耦合通过大量且不断扩展的细胞内和膜结合蛋白来实现复杂的信号事件级联。 GPCR 转导过程的一个共同特征是异源三聚体 G 蛋白的中介。激动剂与 GPCR 结合后,同源 G1 和 G23 亚基的解离或重排被认为会触发各种酶、离子通道和其他效应分子的刺激或抑制。经典受体理论表明,特定 GPCR 的任何激动剂都会诱导相同的构象变化,并且激动剂之间功效和效力的差异仅反映偶联效率(信号强度)和相对结合亲和力。最近关于许多 GPCR 的证据表明存在配体特异性构象,这些构象优先运输受体激活以选择信号通路的子集,从而通过相同的 GPCR 同工型导致不同激动剂的不同信号级联。就人类 D2 多巴胺受体而言,我们发现了 K 通道和 Ca 通道、腺苷酸环化酶和 MAP 激酶在暴露于激动剂喹吡罗、DHX 和 NPA 后的选择性激活模式(效力和内在活性)。激动剂作用的这种“功能选择性”的潜在分子机制尚不清楚。在拟议的研究中,我们将通过四个具体目标来研究神经内分泌 AtT20 细胞系和原代大鼠神经元中功能性受体信号复合物的潜在机制:(1)定义与五个效应器偶联的 D2 和 D3 多巴胺受体的配体依赖性选择性;腺苷酸环化酶 (AC)、Kir3.0 通道、CaV2.0 通道、p42/44 MAP 激酶 (Erk1/2) 和 2-arrestin 易位。 (2) 评估大鼠中脑神经元天然 D2 受体信号传导的功能选择性参数。 (3) 测试跨膜结构域(TM2、TM5、TM7)和细胞内环中的保守残基(先前显示为其他 GPCR 中的信号开关)对通过 D2 受体的激动剂信号传导的功能选择性的贡献。 (4) 检验特定受体/G1 蛋白复合物赋予激动剂依赖性功能选择性的假设。这些实验将增进对分子间相互作用在确定多巴胺能配体的效力和功效方面的作用的理解,进而对针对几种神经精神和内分泌疾病的药物的开发产生影响。
公共健康相关性:本研究探讨了一种称为“功能选择性”的新型信号传导现象的分子基础,通过这种现象,不同的药物和神经递质可以通过相同的神经递质受体亚型引导非常不同的信号传导结果。我们将重点关注与药物滥用行为以及精神分裂症等几种精神疾病广泛相关的一类重要的多巴胺受体。由于受体是药物治疗的重要靶点,我们的研究结果将指导针对这些疾病开发更精细、更特异性、副作用更少的药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GERRY S OXFORD其他文献
GERRY S OXFORD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GERRY S OXFORD', 18)}}的其他基金
Ligand Directed Functional Selectivity of G-Protein Coupled Receptor Signalling
G 蛋白偶联受体信号转导的配体定向功能选择性
- 批准号:
8113250 - 财政年份:2009
- 资助金额:
$ 31.94万 - 项目类别:
Ligand Directed Functional Selectivity of G-Protein Coupled Receptor Signalling
G 蛋白偶联受体信号转导的配体定向功能选择性
- 批准号:
8304950 - 财政年份:2009
- 资助金额:
$ 31.94万 - 项目类别:
Molecular basis of brain sensitization by neurotrophins
神经营养因子脑敏化的分子基础
- 批准号:
6594460 - 财政年份:2002
- 资助金额:
$ 31.94万 - 项目类别:
Molecular basis of brain sensitization by neurotrophins
神经营养因子脑敏化的分子基础
- 批准号:
6470113 - 财政年份:2001
- 资助金额:
$ 31.94万 - 项目类别:
Molecular basis of brain sensitization by neurotrophins
神经营养因子脑敏化的分子基础
- 批准号:
6340077 - 财政年份:2000
- 资助金额:
$ 31.94万 - 项目类别:
相似国自然基金
儿童药品不良反应主动监测中时序处理策略的方法学研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于真实世界医疗大数据的中西药联用严重不良反应监测与评价关键方法研究
- 批准号:82274368
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于隐狄利克雷分配模型的心血管系统药物不良反应主动监测研究
- 批准号:82273739
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于真实世界数据的创新药品上市后严重罕见不良反应评价关键方法研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
OR10G7错义突变激活NLRP3炎症小体致伊马替尼严重皮肤不良反应的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
On-demand nonhormonal male contraception via ADCY10 inhibition
通过 ADCY10 抑制按需非激素男性避孕
- 批准号:
10747153 - 财政年份:2023
- 资助金额:
$ 31.94万 - 项目类别:
A Novel Pharmacological Inhibitor of Adenylyl Cyclase Type 5 to Treat Alzheimer's Disease
一种治疗阿尔茨海默病的新型 5 型腺苷酸环化酶药理抑制剂
- 批准号:
10608477 - 财政年份:2022
- 资助金额:
$ 31.94万 - 项目类别:
Synaptic mechanisms underlying the rapid antidepressant properties of the (2R,6R)-hydroxynorketamine metabolite
(2R,6R)-羟基去甲氯胺酮代谢物快速抗抑郁特性的突触机制
- 批准号:
10227667 - 财政年份:2020
- 资助金额:
$ 31.94万 - 项目类别:
Use of precision deuteration to determine the contribution of norbuprenorphine to buprenorphine-associated neonatal abstinence syndrome
使用精密氘化确定去甲丁丙诺啡对丁丙诺啡相关新生儿戒断综合征的影响
- 批准号:
9980838 - 财政年份:2019
- 资助金额:
$ 31.94万 - 项目类别:
KOR Agonist Functional Selectivity in Peripheral Sensory Neurons
KOR 激动剂在周围感觉神经元中的功能选择性
- 批准号:
9816140 - 财政年份:2018
- 资助金额:
$ 31.94万 - 项目类别: